Clinical trials in ALS: A review of the role of clinical and neurophysiological measurements

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 6, Issue 1 SUPPL. 1, 2005, Pages 202-212

  de Carvalho, Mamede ^a,b,c   Costa, João ^a,c   Swash, Michael ^c  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b Centro de Estudos Egas Moniz   (Portugal)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis; Clinical measurement; Clinical trials; Motor neurone disease; Neurophysiology

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; BCAA; CENTRAL NERVOUS SYSTEM AGENTS; CREATINE; CYCLOSPORIN; GABAPENTIN; GROWTH HORMONE; IMMUNOSUPPRESSIVE AGENT; PLACEBO; RECOMBINANT BETA INTERFERON; RECOMBINANT BRAIN DERIVED NEUROTROPHIC FACTOR; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RECOMBINANT SOMATOMEDIN C; RILUZOLE; SELEGILINE; THREONINE; TOPIRAMATE; UNCLASSIFIED DRUG; XALIPRODEN; 2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; AMANTADINE; BETA1 INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; DEXTROMETHORPHAN; GANGLIOSIDE; GLUTATHIONE; GUANIDINE; LAMOTRIGINE; LEVAMISOLE; MECOBALAMIN; METHISOPRINOL; NIMODIPINE; PROTIRELIN; TILORONE; UNINDEXED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG MEGADOSE; HUMAN; MEDLINE; META ANALYSIS; METHODOLOGY; MORTALITY; NEUROPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STATISTICAL ANALYSIS; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ANALYTIC METHOD; CONTROL GROUP; FREQUENCY ANALYSIS; MEASUREMENT; MEDICAL DECISION MAKING; NONLINEAR SYSTEM; PUBLICATION; SENSITIVITY ANALYSIS;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; HUMANS; NEUROPHYSIOLOGY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 29244435765     PISSN: 14660822     EISSN: 1471180X     Source Type: Journal    
DOI: 10.1080/14660820510011997     Document Type: Review

References (88)

1. Turner, M.R. and Parton, M.J. and Leigh, P.N. (2001) Clinical trials in ALS: An overview. Sem Neurol, 21, pp. 167-75.
2. Miller, R.G. and Munsat, T.L. and Swash, M. and Brooks, B.R. (1999) Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on research. J Neurol Sci, 169, pp. 2-12.
3. Matthews, J.N.S. and ed. (2000). In An Introduction to Randomized Clinical Trials. London: Arnold.
4. Swash, M. (1998) Early diagnosis of ALS/MND. J Neurol Sci, 160(Suppl), pp. S33-6.
5. Appel, S.H. and Stewart, S.S. and Appel, V. and Harati, Y. and Mietlowski, W. and Weiss, W. and Belendiuk, G.W. (1988) A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch Neurol, 45, pp. 381-6.
6. The Italian ALS Study Group. (1993) Branched-chain amino acids and amyotrophic lateral sclerosis: A treatment failure? Neurology, 43, pp. 2466-70.
7. Parton, M. and Mitsumoto, H. and Leigh, P.N. (2004) Amino acids for amyotrophic lateral sclerosis/motor neuron disease. In The Cochrane Library, Issue 4. Chichester: John Wiley & Sons, Ltd.
8. Smith, R.A. and Melmed, S. and Sherman, B. and Frane, J. and Munsat, T. L. and Festoff, B.W. (1993) Recombinant growth hormone treatment of amyotrophic lateral sclerosis. Muscle Nerve, 16, pp. 624-33.
9. Drachman, D.B. and Chaudhry, V. and Cornblath, D. and Kuncl, R.W. and Pestronk, A. and Clawson, L. and (1994) Ann Neurol, 35, pp. 142-50.
10. Bensimon, G. and Lacomblez, L. and Meininger, V. and the ALS/Riluzole study group. (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. New England Journal of Medicine, 330, pp. 585-91.
11. Miller, R.G. and Mitchell, J.D. and Moore, D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). (Cochrane Review). In The Cochrane Library, Issue 4, 2004. Chichester: John Wiley & Sons, Ltd.
12. Louwerse, E.S. and Weverling, G.J. and Bossuyt, P.M. and Meyjes, F.E. and de Jong, J.M. (1995) Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol, 52, pp. 559-64.
13. Orrell, R.W. and Lane, J.M. and Ross, M.A. (2004) Antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester: John Wiley & Sons, Ltd.
14. ALS CNTF Treatment Study Group. (1996) A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology, 46, pp. 1244-9.
15. Bongioanni, P. and Reali, C. and Sogos, V. (2004) Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester: John Wiley & Sons, Ltd.
16. Miller, R.G. and Petajan, J.H. and Bryan, W.W. and Armon, C. and Barohn, R.J. and Goodpasture, J.C. and and the rhCNTF ALS ALS Study Group. (1996) A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann Neurol 39, pp. 256-60.
17. Tandan, R. and Bromberg, M.B. and Forshew, R.N. and Fries, T.J. and Badger, G.J. and Carpenter, J. and (1996) A controlled trial of amino acid therapy in amyotrophic lateral sclerosis. I. Clinical, functional, and maximum isometric torque data. Neurology, 47, pp. 1220-6.
18. Miller, R.G. and Moore, D. and Young, L.A. and Armon, C. and Barohn, R.J. and Bromberg, M.B. and Bryan, W.W. and (1996) Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology, 47, pp. 1383-8.
19. Lacomblez, L. and Bensimon, G. and Leigh, P.N. and Guillet, P. and Meininger, V. (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet, 25(347), pp. 1425-31.
20. Lai, Ec. and Felice, K.J. and Festoff, B.W. and Gawel, M.J. and Gelinas, D.F. and Kratz, R. and (1997) and the North America ALS/IGF-I Study Group. Effects of recombinant human insulin-like growth factor-I on progression of ALS. A placebo controlled study. Neurology, 49, pp. 1621-30.
21. Mitchell, J. D. and Wokke, J. H. J. and Borasio, G. D.(2004) Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease (Cochrane Review). In The Cochrane Library, Issue 4. Chichester: John Wiley & Sons, Ltd.
22. Lange, D.J. and Murphy, P.L. and Diamond, B. and Appel, V. and Lai, E.C. and Younger, D.S. and Appel, S.H. (1998) Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol, 55, pp. 93-96.
23. Borasio, G.D. and Robberecht, W. and Leigh, P.N. and Emile, J. and Guilloff, R.J. and Jerusalem, F. et al (1998) and the European ALS/IGF-I Study Group. A placebo-controlled trial of insulin-like nerve growth factor-1 in amyotrophic lateral sclerosis. Neurology, 51, pp. 583-586.
24. The BDNF Study Group (Phase III). (1999) A controlled trial of recombinant methionyl human BDNF in ALS. Neurology, 52, pp. 1427-1433.
25. Beghi, E. and Chiò, A. and Inghilleri, M. and Mazzini, L. and Micheli, A. and Mora, G. et al (2000) and the Italian Amyotrophic Lateral Sclerosis Study Group. A randomized controlled trial of recombinant interferon beta-1a in ALS. Neurology, 54, pp. 469-474.
26. Miller, R.G. and Moore, D.H. and Gelinas, D.F. and Dronsky, V. and Mendoza, M. and Barohn, R.J., et al (2001) and the Western ALS Study Group. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology, 56, pp. 843-848.
27. Desnuelle, C. and Dib, M. and Garrel, C. and Favier, A. (2001) A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord, 2, pp. 9-18.
28. Groeneveld, G.J. and Veldink, J.H. and van der Tweel, I. and Kalmijn, S. and Beijer, C. and de Visser, M., et al (2003) A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol, 53, pp. 437-445.
29. Cudkowicz, M.E. and Shefner, J.M. and Schoenfeld, D.A. and Brown RH, Jr. and Johnson, H. and Qureshi, M. et al. (2003) and the Northeast ALS Consortium. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology, 61, pp. 456-464.
30. Meiningier, V. and Bensimon, G. and Bradley, W. G. and Brooks, B.R. and Doillet, P. and Eisen, A.A. et al (2004) Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: Results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord, 5, pp. 107-117.
31. Graf, M. and Ecker, D. and Horowski, R. and Kramer, B. and Riederer, P. and Gerlach, M. et al (2004) on behalf of the German vitamin E/ALS study group. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: Results of a placebo-controlled double-blind study. J Neural Transm. published on-line October 27
32. Shefner, J.M. and Cudkowicz, E. and shoenfeld, D. and Conrad, T. and Taft, J. and Chilton, M. et al. (2004) and the NEALS Consortium. A clinical trial of creatine in ALS. Neurology, 63, pp. 1656-1661.
33. de Carvalho, M. and Scotto, M. and Lopes, A. and Swash, M. (2003) Clinical and neurophysiological evaluation of progression in amyotrophic lateral sclerosis. Muscle Nerve, 28, pp. 630-633.
34. de Carvalho, M. and Scotto, M. and Lopes, A. and Swash, M. (2005) Quantifying progression in ALS. Neurology, 64, pp. 1783-1785.
35. Survival, Cedarbaum. (2004) Amyotroph Lateral Scler Other Motor Neuron Disord., 5(Suppl 1), pp. 79-83.
36. Pinto, A.C. and Evangelista, T. and de Carvalho, M. and Alves, M. and Sales-Luís, M. L. (1995) Respiratory assistance with non-invasive ventilation (Bipap) in MND/ALS patients: Survival rate in a controlled trial. J Neurol Sci, 129 (Suppl), pp. 19-26.
37. Desport, J.C. and Preux, P.M. and Truong, C.T. and Courat, L. and Vallat, J.M. and Couratier, P. (2000) Nutritional assessment and survival in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord, 1, pp. 91-96.
38. Munsat, T.L. and Andres, P.L. and Finison, L. and Conlon, T. and Thibodeau, L. (1988) The natural history of motor neuron loss in amyotrophic lateral sclerosis. Neurology, 38, pp. 409-411.
39. Lyall, R.A. and Donaldson, N. and Polkey, M.I. and Leigh, P.N. and Moxham, J. (2001) Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain, 124, pp. 2000-2013.
40. Fitting, J.W. and Paillex, R. and Hirt, L. and Aebischer, P. and Schluep, M. (1999) Sniff nasal pressure: A sensitive respiratory test to assess progression of amyotrophic lateral sclerosis. Ann Neurol, 46, pp. 887-893.
41. Norris FH, Jr. and Calanchini, P.R. and Fallat, R.J. and Panchari, S. and Jewett, B. (1974) The administration of guanidine in amyotrophic lateral sclerosis. Neurology, 24, pp. 721-728.
42. Appel, V. and Stewart, S.S. and Smith, G. and Appel, S.H. (1987) A rating scale for amyotrophic lateral sclerosis: Description and preliminary experience. Ann Neurol, 22, pp. 328-333.
43. Cedarbaum, J.M. and Stambler, N. (1997) Performance of Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials. J Neurol, 152(Suppl 1), pp. S1-S9.
44. Traynor, B.J. and Zhang, H. and Shefner, J.M. and Schoenfeld, D. and Cudkowicz, M. and and EALS Consortium. (2004) Functional outcome measures as clinical trial endpoints in ALS. Neurology, 63, pp. 1933-1935.
45. Swash, M. (1997) Health outcome and quality-of-life measurements in amyotrophic lateral sclerosis. J Neurol, 244(Suppl 2), pp. S26-S29.
46. Miller, R.G. and Moore, D.H. (2004) ALS trial design: Expectation and reality. Amyotroph Lateral Scler Other Motor Neuron Disord, 5(Suppl 1), pp. 52-54.
47. Cedarbaum, J.M. and Stambler, N. and Malta, E. and Fuller, C. and Hilt, D. and Thurmond, B. and Nakanishi, A. (1999) The ALS-FRS: A revised ALS functional rating scale that incorporates assessments of respiratpry function. BNDF ALS Study Group (phase II/III). J Neurol Sci, 169, pp. 13-21.
48. Swash, M. and de Carvalho, M. (2004) The neurophysiological índex in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord, 5(Suppl 1), pp. 10810.
49. de Carvalho, M. and Chio, A. and Dengler, R. and Hecht, M. and Weber, M. and Swash, M.Neurophysiological measures in amyotrophic lateral sclerosis: Markers of progression in clinical trials. Amyotroph Lateral Scler Other Motor Neuron Disord.
50. Swash, M. (2002) What does the neurologist expect from clinical neurophysiology? Muscle Nerve, 11(Suppl), pp. S1348.
51. Fareed, G.C. and Tyler, R. (1971) The use of isoprinosine in patients with amyotrophic lateral sclerosis. Neurology, 21, pp. 937-940.
52. Olson, W.H. and Simons, J.A. and Halaas, G.W. (1978) Therapeutic trial of tilorone: Lack of benefit in a double-blind, placebo-controlled study. Neurology, 28, pp. 1293-1295.
53. Munsat, T.L. and Easterday, C.S. and Levy, S. and Wolff, S.M. and Hiatt, R. (1981) Amantadine and guanidine are ineffective in ALS. Neurology, 31, pp. 1054-1055.
54. Bradley, W.G. ((1984)) Double-blind controlled trial of purified brain gangliosides in amyotrophic lateral sclerosis and experience with peripheral neuropathies. Adv Exp Med Biol, 174, pp. 565-573.
55. Bradley, W.G. and Hedlund, W. and Cooper, C. and Desousa, G.J. and Gabbai, A. and Mora, J.S. et al (1984) A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis. Neurology, 34, pp. 1079-1082.
56. Harrington, H. and Hallett, M. and Tyler, H.R. (1984) Gangliosides therapy for amyotrophic lateral sclerosis: A double-blind controlled trial. Neurology, 34, pp. 1083-1085.
57. Hallett, M. and Harrington, H. and Tyler, H.R. and Flood, T. and Slater, N. (1984) Trials of gangliosides for amyotrophic lateral sclerosis and diabetic neuropathy. Adv Exp Med Biol, 174, pp. 575-579.
58. Imoto, K. and Saida, K. and Iwamura, K. and Saida, T. and Nishitani, H. (1984) Amyotrophic lateral sclerosis: A double-blind crossover trial of thyrotropin-releasing hormone. J Neurol Neurosurg Psychiatry, 47, pp. 1332-1334.
59. Olarte, M.R. and Shafer, S.Q. (1985) Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis. Neurology, 35, pp. 1063-1066.
60. Mitsumoto, H. and Salgado, E.D. and Negroski, D. and Hanson, M.R. and Salanga, V.D. and Wilber, J.F. et al (1986) Amyotrophic lateral sclerosis: Effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials. Neurology, 36, pp. 152-159.
61. Brooke, M.H. and Florence, J.M. and Heller, S.L. and Kaiser, K.K. and Phillips, D. and Gruber, A. et al (1986) Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis. Neurology, 36, pp. 146-151.
62. Caroscio, J.T. and Cohen, J.A. and Zawodniak, J. and Takai, V. and Shapiro, A. and Blaustein, S. et al (1986) A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis. Neurology, 36, pp. 141-145.
63. Norris, F.H. and Denys, E.H. and Fallat, R.J. (1986) Trial of octaconasol in amyotrophic lateral sclerosis. Neurology, 36, pp. 1263-1264.
64. Plaitakis, A. and Smith, J. and Mandeli, J. and Yahr, M.D. (1988) Pilot trial of branched-chain amino acids in amyotrophic lateral sclerosis. Lancet, 1, pp. 1015-1018
65. Lacomblez, L. and Bouche, P. and Bensimon, G. and Meininger, V. (1989) A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis. Neurology, 39, pp. 1635-1637.
66. Blin, O. and Serratrice, G. and Pouget, J. and Aubrespy, G. and Guelton, C. and Crevat, A. (1989) Short-term double-blind vs. placebo trial of L-threonine in amyotrophic lateral sclerosis. Presse Med, 30, pp. 1469-1470.
67. Testa, D. and Caraceni, T. and Fetoni, V. (1989) Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis. J. Neurol, 236, pp. 445-447.
68. Blin, O. and Desnuelle, C. and Guelton, C. and Aubrespy, G. and Ardissonne, J.P. and Crevat, A. et al (1991) Anomalie des acides amines neurotransmetteurs dans la slerose lateral amyotrophique: Une application therapeutique. Rev Neurol, 147, pp. 392-394.
69. Blin, O. and Pouget, J. and Aubrespy, G. and Guelton, C. and Crevat, A. and Serratrice, G. (1992) A double-blind placebo-controlled trial of L-threonine in amyotrophic lateral sclerosis. J. Neurol, 239, pp. 79-81.
70. Gil, R. and Neau, J.P. and Courtois, P. and Gaucher, C. and Jonveaux, T. and Rosolacci, T. et al (1992) Essai en double aveugle contre placebo des acides amines branches et de la L-threonine dans le traitment des signes et symptomes de la sclerose lateral amyotrophique sur un courte periode. Sem Hop Paris, 68, pp. 1472-1475.
71. Testa, D. and Caraceni, T. and Fetoni, V. and Girotti. (1992) Chronic treatment with L-threonine in amyotrophic lateral sclerosis: A pilot study. Clin Neurol Neurosurg, 94, pp. 7-9.
72. Blin, O. and Pouget, J. and Aubrespy, G. and Guelton, C. and Crevat, A. and Serratrice, G. (1992) A double-blind placebo-controlled trial of L-threonine in amyotrophic lateral sclerosis. J Neurol, 239, pp. 79-81.
73. Askmark, H. and Aquilonius, S.M. and Gillberg, P.G. and Liedholm, L.J. and Stalberg, E. and Wuopio, R. (1993) A pilot trial of dextromethorphan in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry, 56, pp. 197-200.
74. Hesselmans, L.F. and Wieneke, G.H. and Oey, P.L. and Groenhout, D.M. and van der Graaf, Y. and Gispen, W.H. and Jennekens, F.G. (1993) Evaluation of electrophysiological and clinical tests in an exploratory trial of Org 2766 in motor neuron disease. Neuromuscul Disord, 3, pp. 319-325.
75. Eisen, A. and Stewart, H. and Schulzer, M. and Cameron, D. (1993) Anti-glutamate therapy in amyotrophic lateral sclerosis. Can J Neurol Sci, 20, pp. 297-301.
76. Mazzini, L. and Testa, D. and Balzarini, C. and Mora, G. (1994) An open.randomized clinical trial of selegiline in amyotrophic lateral sclerosis. J Neurol, 241, pp. 223-227.
77. Jossan, S.S. and Ekblom, J. and Gudjonsson, O. and Hagbarth, K.E. and Aquilonius, S.M. (1994) Double-blind crossover trial with deprenyl in amyotrophic lateral sclerosis. J Neural Transm, 41, pp. 237-241.
78. Miller, R.G. and Shepherd, R. and Dao, H. and Khramstov, A. and Mendonza, M. and Graves, J. and Smith, S. (1996) Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromusc Disord, 6, pp. 101-104.
79. Blin, O. and Azulay, J.P. and Desnuelle, C. and Bille-Turc, F. and Braguer, D. and Besse, D. et al (1996) A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis. Clin Neuropharmacol, 19, pp. 189-192.
80. Gredal, O. and Werdelin, L. and Bak, S. and Christensen, P.B. and Boysen, G. and Kristensen, M.O. et al (1997) A clinical trial of dextromethorphan in amyotrophic lateral sclerosis. Acta Neurol Scand, 96, pp. 8-13.
81. Kaji, R. and Kodama, M. and Imamura, A. and Hashida, T. and Kohara, N. and Ishizu, M. et al (1998) Effect of ultra-high dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: A double-blind controlled study. Muscle Nerve, 21, pp. 1775-1778.
82. Chio, A. and Cucatto, A. and Terreni, A.A. and Schiffer, D. (1998) Reduced glutathione in amyotrophic lateral sclerosis: An open, crossover, randomized trial. Ital J Neurol Sci, 19, pp. 363-366.
83. Bensimon, G. and Lacomblez, L. and Delumeau, J.C. and Bejuit, R. and Truffinet, P. and Meininger, V. (2002) Riluzole/ALS Study Group. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. Journal of Neurology, 249, pp. 609-615.
84. Ryberg, H. and Askmark, H. and Persson, L.I. (2003) A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: Effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol Scand, 108, pp. 1-8.
85. Yuen, E.C. and Olney, R.K. (1997) Longitudinal study of fibre density and motor unit number estimate in patients with amyotrophic lateral sclerosis. Neurology, 49, pp. 573-578.
86. Felice, K.J. (1997) A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosis. Muscle Nerve, 20, pp. 179-185.
87. Bromberg, M.B. and Fries, T.J. and Forshew, D.A. and Tandan, R. (2001) Electrophysiological endpoint measures in a multicentre ALS drug trial. J Neurol Sci, 184, pp. 51-55.
88. Shefner, J.M. and Cudkowicz, M.E. and Zhang, H. and Schoenfeld, D. and Jillapalli, D. and Northeast ALS Consortium. (2004) The use of statistical MUNE in a multicentre clinical trial. Muscle Nerve, 30, pp. 463-469.